Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > Teva might take a run at cxr
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by smallshorton Nov 01, 2016 11:00am
66 Views
Post# 25410059

RE:RE:Teva might take a run at cxr

RE:RE:Teva might take a run at cxrRun for the assets not stock right?  Why would anyone want to take on all the debt when assets are reported to be less?

Health123 wrote: Yah I heard the same thing.  Teva's competing generic isn't scheduled to be approved until early 2017 so it shouldn't negatively start affect Cxr's transaction/volumes until 2H 2017.  So no immediate worries.
fundtrader wrote:
talking to some guys last nite..i think something might happen between them soon




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities